European Commission Alzheimer’s drug approval marks advancement for EU patients

**European Commission Approves Lecanemab for Alzheimer’s Treatment in EU**

The European Commission has granted approval for lecanemab, a monoclonal antibody designed to treat Alzheimer’s disease. The drug is notable for its ability to selectively bind to and clear toxic protofibrils associated with the progression of the condition. This marks the first approval of an amyloid-beta (Aβ) monoclonal antibody in the European Union that targets these specific protein aggregates.

Lecanemab works by targeting protofibrils, which are considered a key contributor to neurodegeneration in Alzheimer’s patients. Its high selectivity allows it to effectively remove these toxic structures while minimizing interaction with other forms of amyloid-beta proteins. This mechanism distinguishes lecanemab from other treatments currently available for Alzheimer’s disease. The approval follows clinical evaluations that demonstrated its efficacy in addressing early stages of the disease, offering new therapeutic options for patients across EU member states.

Further details on this development can be accessed through official sources reporting on the decision.

Newsflash | Powered by GeneOnline AI

Source: https://www.europeanpharmaceuticalreview.com/news/252759/european-commission-alzheimers-drug-approval-marks-advancement-for-eu-patients/

Author

Mark Chiang